IN2014CN04823A - - Google Patents

Info

Publication number
IN2014CN04823A
IN2014CN04823A IN4823CHN2014A IN2014CN04823A IN 2014CN04823 A IN2014CN04823 A IN 2014CN04823A IN 4823CHN2014 A IN4823CHN2014 A IN 4823CHN2014A IN 2014CN04823 A IN2014CN04823 A IN 2014CN04823A
Authority
IN
India
Prior art keywords
rsv
hybridoma
secreted
relates
monoclonal antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Parra Alexis Mikes Kalergis
Ramirez Susan Marcela Bueno
Alarcon Jorge Eugenio Mora
Johnson Roberto Sebastián Gómez
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of IN2014CN04823A publication Critical patent/IN2014CN04823A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
IN4823CHN2014 2011-11-25 2012-11-23 IN2014CN04823A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2011003002A CL2011003002A1 (es) 2011-11-25 2011-11-25 Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
PCT/IB2012/056688 WO2013076702A2 (es) 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs)

Publications (1)

Publication Number Publication Date
IN2014CN04823A true IN2014CN04823A (enExample) 2015-09-18

Family

ID=51205767

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4823CHN2014 IN2014CN04823A (enExample) 2011-11-25 2012-11-23

Country Status (13)

Country Link
US (1) US9273122B2 (enExample)
EP (1) EP2784088B1 (enExample)
CN (1) CN103998465B (enExample)
AR (1) AR088987A1 (enExample)
CA (1) CA2856258C (enExample)
CL (1) CL2011003002A1 (enExample)
ES (1) ES2657619T3 (enExample)
IN (1) IN2014CN04823A (enExample)
MX (1) MX349235B (enExample)
PE (1) PE20141683A1 (enExample)
PT (1) PT2784088T (enExample)
WO (1) WO2013076702A2 (enExample)
ZA (1) ZA201403564B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014003373A1 (es) * 2014-12-11 2015-04-10 Univ Pontificia Catolica Chile Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.
JP6270781B2 (ja) * 2015-06-30 2018-01-31 田中貴金属工業株式会社 クロマト分析装置およびクロマト分析方法
CL2015002152A1 (es) 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3848389A4 (en) 2018-09-03 2022-04-13 Pontificia Universidad Católica De Chile SPECIFIC MONOCLONAL ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) N-ANTIGEN FOR TREATMENT, DETECTION AND DIAGNOSIS OF INFECTION
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
CN115838419B (zh) * 2022-09-27 2023-06-30 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686113B2 (en) * 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
NZ269735A (en) 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
AU3005500A (en) * 1999-02-26 2000-09-14 Uab Research Foundation, The Methods of screening for antiviral compounds
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
AU1038402A (en) 2000-10-17 2002-04-29 Besst Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
JP2007531491A (ja) * 2002-09-27 2007-11-08 メディミューン・ヴァクシンズ・インコーポレーテッド 呼吸器合胞体ウイルスにおける機能的突然変異
CN101130765B (zh) 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체

Also Published As

Publication number Publication date
US20140348858A1 (en) 2014-11-27
WO2013076702A2 (es) 2013-05-30
MX2014006248A (es) 2015-03-03
EP2784088A2 (en) 2014-10-01
AR088987A1 (es) 2014-07-23
EP2784088A4 (en) 2015-05-13
ZA201403564B (en) 2015-08-26
ES2657619T3 (es) 2018-03-06
PE20141683A1 (es) 2014-11-28
CN103998465B (zh) 2017-02-22
PT2784088T (pt) 2018-01-31
US9273122B2 (en) 2016-03-01
MX349235B (es) 2017-07-19
CA2856258A1 (en) 2013-05-30
WO2013076702A3 (es) 2013-07-25
EP2784088B1 (en) 2017-10-25
CL2011003002A1 (es) 2012-05-25
CA2856258C (en) 2018-05-01
BR112014012608A2 (pt) 2020-10-27
CN103998465A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
Eisenberg et al. Rituximab-treated patients have a poor response to influenza vaccination
WO2013076702A3 (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs)
CN105050622B (zh) 针对呼吸道融合病毒f蛋白质的人类抗体及其使用方法
Perricone et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases
Glenn et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
US20210130441A1 (en) Compositions and methods for the treatment of immunodeficiency
Valentini et al. Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblings
Grasse et al. Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults
Caidi et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
Zhao et al. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model
Leroux-Roels et al. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study
Tabata et al. Neutralizing monoclonal antibodies reduce human cytomegalovirus infection and spread in developing placentas
Su et al. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
Parreno et al. Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
Torrey et al. Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein
Changrob et al. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
Barros-Martins et al. Omicron infection-associated T-and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
Valats et al. Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination
Moazen et al. Single chain antibodies against gp55 of Human Cytomegalovirus (HCMV) for prophylaxis and treatment of HCMV infections
CA3173861A1 (en) Natural antibodies in prophylaxis and therapy
WO2013035345A3 (en) Dengue-virus serotype neutralizing antibodies
Launay et al. Factors associated with humoral immune response to pandemic A/H1N1 (v) 2009 influenza vaccine in cystic fibrosis
Rinaldi et al. B-sides serologic markers of immunogenicity in kidney transplanted patients: report from 2012–2013 flu vaccination experience
WO2017084518A1 (zh) 一种疫苗佐剂以及包含该佐剂的疫苗